Related Experiment Videos
Chemoradiotherapy for cervical cancer.
1Division of Gynecologic Oncology, University Hospitals of Cleveland and The Ireland Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA. peter.rose@uhhs.com
European Journal of Cancer (Oxford, England : 1990)
|January 23, 2002
Summary
Cisplatin-based chemoradiation significantly improves survival for locally advanced cervical cancer patients by 30-50%. This treatment is now the standard of care, offering better outcomes despite transient acute toxicities.
Area of Science:
- Gynecologic Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Cervical cancer poses a significant global health challenge, particularly in locally advanced stages where local-regional control is critical for survival.
- Despite screening advancements, treatment failures in advanced cervical cancer often lead to mortality.
- Neoadjuvant and concurrent chemoradiation strategies have been explored to enhance local-regional tumor control.
Purpose of the Study:
- To evaluate the efficacy and safety of cisplatin-based chemoradiation in patients with locally advanced cervical cancer.
- To determine if concurrent chemoradiation improves survival outcomes compared to radiation alone or radiation with hydroxyurea.
Main Methods:
- Analysis of five randomized trials conducted by the Gynecologic Oncology Group (GOG), Radiation Therapy Oncology Group (RTOG), and SouthWest Oncology Group (SWOG).
- Comparison of cisplatin-based concurrent chemoradiation against radiation therapy alone or radiation therapy with hydroxyurea.
- Assessment of survival advantage, acute toxicities (e.g., neutropenia, gastrointestinal), and late complications.
Main Results:
- Cisplatin-based chemotherapy administered concurrently with radiation therapy demonstrated a significant survival advantage, reducing the risk of death by 30-50% across all trials.
- Acute toxicities, primarily neutropenia and gastrointestinal issues, were more frequent with chemoradiation but were transient.
- Rates of late complications were comparable between chemoradiation and control groups.
Conclusions:
- Cisplatin-based chemoradiation is a highly effective treatment for locally advanced cervical cancer, significantly improving survival.
- The National Cancer Institute (NCI) has endorsed cisplatin-based chemotherapy, delivered concurrently with radiation, as the new standard of care for cervical cancer based on these findings.